Experts in clinical genetics and molecular diagnostics usher in new era of cancer care
Already, some Upstate patients take drugs that fight cancer not by killing cancer cells but by allowing their immune systems to put the brakes on cancer’s growth. Some patients undergo simple blood tests known as liquid biopsies to check for traces of cancer DNA. Some have tissue specimens analyzed by clinical geneticists. Some receive treatment recommendations from cancer doctors who confer with molecular pathologists about which drugs are most likely to work best.
“Upstate provides access to the most advanced testing and therapeutic options,” Robert Corona, DO, interim chief executive officer and pathology chair, told community leaders in a presentation recently. As leader of the medical center’s pathology department, he is raising the quality of cancer diagnostics for patients in the region to be on par with leading national institutions.
How? Through the recruitment of experts in clinical genetics and molecular diagnostics.
Steven Sperber, PhD, is a clinical molecular geneticist who is bringing to the molecular pathology laboratory at Upstate “next generation sequencing.” Instead of examining a single gene, next generation sequencing creates a molecular profile of dozens, hundreds or even thousands of genes at once. It’s faster, easier and provides more complete analysis, Sperber explains, and the results can be complex.
He completed his clinical molecular genetics fellowships at the National Human Genome Research Institute in 2009 and worked in diagnostics testing laboratories and academia before joining Upstate last fall. His doctorate in cellular and molecular medicine is from the University of Ottawa.
“Our big goal is to get a profile of a tumor, whether it’s a solid tumor, a lymphoma or a blood-related cancer,” Sperber says. The job then becomes finding and interpreting the mutations, particularly those for which clinical therapies are available.
A growing number of medications with companion diagnostics are receiving approval from the Food and Drug Administration. Patients have to be tested before they can receive the drug. The first of these so-called precision treatments was approved in 1998. The drug, Herceptin, treats an aggressive form of breast cancer; its companion diagnostic looks for a particular protein or extra copies of a particular gene in a patient’s tumor to predict whether Herceptin will be effective.
Then there are the “tissue agnostic” therapies, the first of which — Keytruda — was approved in May 2017. It’s meant to treat solid tumors bearing a specific genetic marker, regardless of where they arise.
Jeffrey Ross, MD, is a molecular pathologist. He leads the Upstate Cancer Center’s monthly “molecular tumor board” meetings. That’s when a team of cancer doctors gathers to discuss treatment options for patients whose DNA has been sequenced. Ross describes the mutations and how they may impact the selection of treatment for each individual. Together, the team comes up with a precision treatment recommendation.
“Instead of the one-size-fits-all approach and the sequential use of drugs based on the performance of the previous regimen, now we want to give each patient a custom-designed treatment that’s essentially driven by the genomic makeup of their cancer,” explains Ross. He went to medical school at the University of Buffalo and is board certified in anatomic pathology and clinical pathology. He joined Upstate this year.
Most patients whose cases are discussed at the molecular tumor board have advanced cancers that have either spread or been treated and relapsed. Precision treatment —also sometimes called personalized medicine — can prolong their lives.
Ross says pharmaceutical companies are excited about making these drugs because “the patient often transitions from what is an acute and possibly fatal disease into a chronic and survivable disease. The drug becomes a maintenance drug, meaning the patient never goes off treatment but lives months or years or tens of years while still on the drug — which makes that, of course, very financially attractive to drug makers.”
The most direct application of sequencing DNA from cancer cells applies to anti-cancer drugs, but Ross says radiation therapy is sometimes also impacted.
“Radiation can now be given to increase the number of mutations in the patient’s cancer, which will then help immunize the patient against their own cancer cells. And then, when the immunotherapy drugs are given, the patient starts to reject their own cancer like it was a transplanted organ from an unrelated donor.”